Ligand Pharmaceuticals Inc. Announces Successful First-In-Human Trial Results For Glucagon Program

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced data from a Phase 1 clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus, and also demonstrate a robust response on fasting plasma glucose after a single dose. LGD-6972 is Ligand’s novel glucagon receptor antagonist and these first-in-human data were presented at the American Diabetes Association’s 74th Scientific Sessions meeting underway in San Francisco.

Help employers find you! Check out all the jobs and post your resume.